Raymon Heather 4

What Happened
Raymon Heather, Senior Vice President of Research and Development at Artiva Biotherapeutics (ARTV), sold 3,095 shares on 2026-05-19 in an open market/private sale. The reported total proceeds were $27,879. This transaction was a sale (not a purchase) and was executed to cover tax withholding related to the vesting/release of restricted stock units.

Key Details

• Transaction date: 2026-05-19 (filed same day)
• Transaction type/code: Sale (S) — sell-to-cover to satisfy tax withholding (automatic, not at the insider’s discretion) [Footnote F1]
• Shares sold: 3,095
• Price: weighted average $9.0078; reported range $8.7447–$9.0104 [Footnote F2]
• Proceeds: $27,879
• Shares owned after transaction: not disclosed in this filing
• Filing timeliness: filing date equals transaction date; no late filing indicated
• Additional note: issuer can provide full breakdown of number of shares sold at each separate price upon request (per F2)

Context
This sale was an automatic "sell-to-cover" tied to tax withholding on RSU vesting, which is routine and does not necessarily indicate a change in insider confidence. For retail investors, purchases typically carry more weight as bullish signals; routine tax-related sales like this are common and primarily administrative.